

A large, circular, semi-transparent image of a woman with long brown hair, wearing a white lab coat and blue gloves, looking down. This image is overlaid with several concentric dark blue circles that frame the text.

***Transforming
Care, Saving Lives***

***Revitalising UK Life
Sciences and Diagnostics***

December 2024

revvity



Innovative solutions for Life Sciences and Diagnostics



Maternal Fetal Health



Newborn Screening




Drug Discovery



**Next Generation
Sequencing**



Gene Editing



**Infectious Disease
Research**

www.revvity.com

Contents

Foreword	1
Headline Recommendations	4
Introduction	6
1. Embed Clinical Research at the Centre of the NHS	7
2. Ensure Rapid Access to and Uptake of Diagnostic Tools	7
3. Harness the Power of Data	8
4. Embrace the Potential of Artificial Intelligence (AI)	9
5. Invest in Jobs and Growth	10
6. Implement a Cutting-edge Regulatory Environment	10
7. Driving Uptake of New Technologies	10
8. Introduce the Latest Scientific Breakthroughs to Identify and Treat Rare Diseases	11
9. Support the Development of Cell and Gene Therapies	12
10. Deliver on the Promise of Personalised Medicines	13
11. Encourage Widespread Use of Whole Genome Sequencing (WGS)	14
12. Promote the Use of Newborn Screening	16
Conclusion	17
Endnotes	18
About Curia	19



Foreword

Revitalising the NHS: A 10-Year Vision for Healthcare Transformation

With the election of the first Labour Government in fourteen years, we find ourselves at a defining moment for the future of the NHS. While the challenges remain significant – escalating patient waitlists, workforce shortages, and a health system struggling to keep pace with rising demand – there is now an opportunity to set a decisive new direction. The Government's forthcoming 10-year plan for health and care, due to be published next year, offers the chance to address these issues head-on, revitalising the NHS and ensuring it is fit for the future.

The challenges cannot be overstated. The NHS, once a symbol of world-class health services, now faces an unprecedented crisis. Staff shortages, growing waiting times, and declining patient satisfaction have created an unsustainable situation, one that threatens not only the efficacy of healthcare services but also the economic stability of the nation. Poor health outcomes and inequality in access undermine productivity and growth, compounding the urgency for reform.

The new Secretary of State for Health and Social Care, Rt Hon Wes Streeting MP has boldly highlighted on several occasions that the NHS is “broken”. Fixing the system is clearly a priority for the Government and as it reviews the responses to the Change NHS: A Health Service Fit for the Future consultation, there is much to consider when it comes to one of the most important and overlooked parts of the healthcare system – diagnostics. The Chancellor's vision to implement the Government's ambitious Missions-based approach through industrial strategies is bold. If delivered through language that resonates with all levels of the NHS, the Life Sciences Industrial Strategy will be transformational for patient outcomes. Combined with a fresh approach towards diagnostics and investment, the UK has the opportunity to become world leading.

Yet, this is not a time for despair. The potential for transformation has never been greater. Innovation in technology, a renewed focus on collaboration, and a fundamental rethinking of how we deliver health services can pave the way for a brighter future. By leveraging cutting-edge diagnostic tools, data-driven decision-making, and advances in genomics, we can drive efficiency, improve outcomes, and create a more sustainable healthcare system.

Revvity, whose contributions were essential to this report, exemplifies this transformative approach. Their work in diagnostics, genomics, and data integration, combined with a collaborative ethos, showcases the potential of the life sciences and diagnostics sector to lead the way. By bridging the gap between research, technology, and patient care, they are already delivering tangible benefits for both patients and health systems.

This report serves not only as a call to action but also as a roadmap for change. It offers practical recommendations to support the Government's vision of a reformed NHS – one that gives mental and physical health equal priority, invests in prevention, and places patients at its heart.

The road ahead will not be easy, but with collective effort, sustained innovation, and a commitment to transformation, we can secure a thriving future for the NHS and the millions of people who depend on it. This report sets out ideas for a decade of progress, driven by partnership and ambition.

**Curia www.curiauk.com
Health, Care and Life Sciences Research Group
Advisory Board**

About Revvity

At Revvity, we are daring to reimagine how diseases can be identified, treated, and cured. By working collaboratively with academics, drug developers, clinicians, clinical labs and governments, we are creating the foundations for change to improve the lives of people around the world.

Revvity is a US-headquartered company that provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. With 2023 revenue of more than \$2.7 billion, and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech industries, diagnostic labs, academia, and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

At Revvity, our vision is to make that world a reality by empowering scientists to reimagine healthcare. We provide the technology and services that support:

- Affordable treatments that reach the market rapidly. Today, our technologies help to ensure the right drugs are selected for development, by implementing better biological models or identifying root causes of disease – reducing risk and cost.
- Screen /diagnose diseases, support maternal and newborn health and next generation sequencing for newborn screening research.
- Novel therapeutic development to help treat and cure disease. Our technologies and expertise help develop new drug modalities and bring revolutionary cell and gene therapy treatments to patients all over the world.
- Precision medicine approaches – matching patients to the best treatment for them. Today, our technologies help to identify critical biomarkers that can be used for clinical assessments so that each individual gets the right drug, at the right time.

Our life sciences and diagnostics portfolios are built on a legacy of innovation, Revvity's technology platforms – centred on cell, protein, and genomic analysis – currently support more than 45,000 peer-reviewed publications every year and provide solutions to help tackle the huge investments required to bring a drug to market. This is why we see our solutions being applied in over 90 per cent of the world's top 50 academic institutions and pharmaceutical companies.

Revvity technologies support over 45,000 life sciences publications annually




Figure 1: Illustrates the number of peer-reviewed publications that utilize Revvity's life sciences technologies to understand disease better.




Figure 2: Provides a breakdown of the 45,000 life sciences peer reviewed publications in 2022 by technology area.